Reinhard von Roemeling

Chief Tech/Sci/R&D Officer presso CURIS, INC.

Health Technology

Consumer Services

Profilo

Reinhard von Roemeling is currently the Senior Vice President-Clinical Development at Curis, Inc. He was previously the Global Head-Research & Development at HUYA Bioscience International LLC.
Dr. von Roemeling holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main.

Posizioni attive di Reinhard von Roemeling

Società	Posizione	Inizio
CURIS, INC.	Chief Tech/Sci/R&D Officer	13/08/2019

Tutte le posizioni attive di Reinhard von Roemeling

Precedenti posizioni note di Reinhard von Roemeling

Società	Posizione	Fine
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Chief Tech/Sci/R&D Officer	-

Vedi nel dettaglio l'esperienza di Reinhard von Roemeling

Formazione di Reinhard von Roemeling

Johann Wolfgang Goethe-Universität Frankfurt am Main

Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Reinhard von Roemeling

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
CURIS, INC.	Health Technology

Aziende private	1
HUYA Bioscience International LLC HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA.	Health Technology